Metropolis Healthcare (Mid Cap - High Growth) Share Target 2026, 2027 To 2035
|
Metropolis Healthcare Limited |
|||
|
Price: ₹525.90 (-0.9%) | ||
| 52 Week Low: ₹412.25 52 Week High: ₹600.00 |
|||
| Market Capital: 9,790.01 Crore (Mid-cap) | |||
| Healthcare -> Diagnostics & Research | |||
Metropolis Healthcare Stock Comparison: Metropolis Healthcare vs Vijaya Diagnostic Centre | Metropolis Healthcare vs Thyrocare Technologies | Metropolis Healthcare vs Krsnaa Diagnostics | Metropolis Healthcare vs Jupiter Life Line Hospitals Limited | Metropolis Healthcare vs Blue Jet Healthcare | Metropolis Healthcare vs Wockhardt |
|||
Share Price HistoryMETROPOLIS FinancialsTomorrow TargetYearly TargetsDividend HistoryNo BonusNo Split
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Metropolis Healthcare Share Price Target For 2026
- 1.1.1: Metropolis Healthcare Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Metropolis Healthcare Share Price Target For 2027
- 1.2.1: Metropolis Healthcare Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Metropolis Healthcare Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Metropolis Healthcare Brief Company Overview
- 4: Metropolis Healthcare Financial Performance
- 4.0.1: Is Metropolis Healthcare A Good Buy For Long Term?
Metropolis Healthcare, a Mid Cap company in the Diagnostics & Research Industry has delivered 57.0% returns in 3-year showing 13.4% quarterly revenue growth with 11.5% profit margin, making it a High Growth stock.
To predict the Metropolis Healthcare's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Metropolis Healthcare Share Price Target For 2026
The line chart displays the monthly closing prices of Metropolis Healthcare with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Metropolis Healthcare shares in 2026, see the table below.
Metropolis Healthcare Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 574.11 (+9.16%) | Volatility: ATR T1 |
| 2026 Target 2 | 552.57 (+5.07%) | Volatility: BB Upper |
| 2026 Target 1 | 529.82 (+0.74%) | Trend: EMA9 |
| Current Price | 525.90 | Metropolis Healthcare's share price as of 15 Jun 2026 |
| Stop Loss 1 | 510.40 (-2.95%) | Volatility: BB Lower |
| Stop Loss 2 | 506.35 (-3.72%) | Trend: SMA50 |
| Stop Loss 3 | 506.12 (-3.77%) | 50.00% Weekly Fib Retrace |
Short-Term Technical Outlook
Current Technical Position: Metropolis Healthcare is showing mixed momentum signals near key moving averages.
Key Technical Level: The 50-day moving average at ₹506.35 serves as the nearest technical reference point.
Historical Returns: 3-month: +14.36% | 6-month: +9.6% | 1-year: +24.89%
Metropolis Healthcare Share Price Target For 2027
The line chart displays the monthly closing prices of Metropolis Healthcare with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Metropolis Healthcare shares in 2027, see the table below.
Metropolis Healthcare Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 574.11 (+9.16%) | Volatility: ATR T1 |
| 2027 Target 2 | 552.57 (+5.07%) | Volatility: BB Upper |
| 2027 Target 1 | 529.82 (+0.74%) | Trend: EMA9 |
| Current Price | 525.90 | Metropolis Healthcare's share price as of 15 Jun 2026 |
| Stop Loss 1 | 510.40 (-2.95%) | Volatility: BB Lower |
| Stop Loss 2 | 506.35 (-3.72%) | Trend: SMA50 |
| Stop Loss 3 | 506.12 (-3.77%) | 50.00% Weekly Fib Retrace |
Long-Term Technical Outlook
52-Week Range Analysis: Metropolis Healthcare is currently trading at 60.5% of its 52-week range (₹412.25 - ₹600).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +24.89% | 3-year: +56.99% | 5-year: -23.14%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Metropolis Healthcare Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹525.90 | ||
| 2026 | ₹667.79 | +26.980414527477% | ₹677.81 |
| 2027 | ₹935.27 | +40.054508153761% | ₹949.30 |
| 2028 | ₹1,052.91 | +12.578185978381% | ₹1,068.70 |
| 2029 | ₹1,392.87 | +32.287659913953% | ₹1,413.76 |
| 2030 | ₹1,709.13 | +22.705636563355% | ₹1,734.77 |
| 2031 | ₹2,295.65 | +34.316874667228% | ₹2,330.08 |
| 2032 | ₹2,965.16 | +29.164288981334% | ₹3,009.64 |
| 2033 | ₹3,396.35 | +14.541879696205% | ₹3,447.30 |
| 2034 | ₹3,932.71 | +15.79224755988% | ₹3,991.70 |
| 2035 | ₹4,507.16 | +14.606975851258% | ₹4,574.77 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Metropolis Healthcare Brief Company Overview
Metropolis Healthcare Limited: A Trusted Diagnostic Provider Metropolis Healthcare Limited is a leading diagnostic services provider in India. Established in 1981, the company has a strong market presence and a reputation for excellence. Key products and services...
include: Clinical laboratory testing: Oncology, neurology, gynecology, nephrology Health check-up packages: Men, women, senior citizens, youth, corporates Corporate wellness and hospital laboratory solutions Clinical research services Metropolis Healthcare is committed to providing accurate, reliable, and timely diagnostic services. With its diverse product range and commitment to excellence, the company is well-positioned to meet the growing demand for diagnostic services in India.Metropolis Healthcare Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 10,373.68 Crore | Market valuation of Metropolis Healthcare's shares. |
| Revenue (TTM) | 1,285.26 Crore | Total revenue generated by Metropolis Healthcare over the past twelve months. |
| Net Income (TTM) | +148.03 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 18.02% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 11.51% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+13.4% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+31.2% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
15.95 | Company's total debt divided by total shareholder equity. |
| Total Debt | 189.46 Crore | Sum of Metropolis Healthcare's current & long-term financial obligations. |
| Total Cash | 184.52 Crore | Total amount of liquid funds available to Metropolis Healthcare. |
| Beta | 0.34 | Beta is less than 1 indicating that the Metropolis Healthcare's price is less volatile than the market. |
Is Metropolis Healthcare A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
